 hem updat track
messag larg increment luxturna sale pre-
report jan co ramp patient identif effort
doubl sale forc focu remain upcom data
hemophilia program includ patient treat expans
arm track mid year still tbd earlier pipelin co
narrow timelin ind progress maintain
buy rate lower pt
luxturna focus expand patient identif effort doubl number
sale rep support genet test innov price propos
remain review propos program includ three- five-year instal
outcomes-bas perform plan
pipelin updat fda inspect clear suspens manufactur
compani narrow window ind file april in-lin
previou guidanc ind-en work gmp materi
expect avail back half previou guidanc compani
also announc undisclos program similar characterist
hemophilia studi run-in studi initi expand
evalu materi made suspens process standard prophylact steroid
regimen updat prior dose per
hemophilia inhibitor program updat
fidanacogen elaparvovec hemophilia pivot trial on-going
chm long-term data present medic confer
pomp spark plan initi us eu phase clinic trial adult
patient follow complet glp toxicolog studi
complet inden work gmp materi avail
result spark report revenu versu our/street estim
dilut ep versu our/street estim
year end compani yet receiv mileston novn-sw
luxturna approv eu spark end year cash equival
model chang updat model reflect result also
decreas estim around patient though also increas valu
assign platform manufactur scale complet earlier stage
pipelin appear track
page analyst certif import disclosur
target price per share base blend averag sum-of-the-part sotp peak revenu analysi well
probabl weight dcf peak revenu analysi appli multipl peak sale us eu assum
discount rate sum-of-the-part basi arriv vs prior luxturna fidanacogen
elaparvovec probabl success vs prior vs prior po vs prior rest
deriv tech platform valu cash dcf forecast probability-weight revenu expens
assum discount rate vs prior termin growth rate
spark suscept risk appli entir biotech industri includ develop regulatori commerci
manufactur financ ip risk specif includ
commerci risk possibl luxturna may success penetr market underdiagnos patient
identif may slower expect payor dynam gene therapi gene edit therapi still emerg luxturna
clinic risk risk downsid includ delay clinic trial initi enrol unexpect safeti issu may aris
efficaci lower expect
regulatori risk even clinic trial ultim success possibl onc medicin approv global
regulatori agenc given novelti technolog agenc may requir addit long-term data could delay potenti
page analyst certif import disclosur
mm except per share data
factset consensu
interest incom incom net
incom tax
factset consensu
cog tot prod sale
 tot revenu
sg tot revenu
compani report guggenheim secur llc estim
page analyst certif import disclosur
